Nuveen Asset Management LLC Buys 11,332 Shares of Oyster Point Pharma (NASDAQ:OYST)
Nuveen Asset Management LLC boosted its stake in shares of Oyster Point Pharma (NASDAQ:OYST) by 85.6% in the second quarter, Holdings Channel reports. The firm owned 24,572 shares of the company’s stock after acquiring an additional 11,332 shares during the period. Nuveen Asset Management LLC’s holdings in Oyster Point Pharma were worth $709,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Signaturefd LLC bought a new stake in Oyster Point Pharma during the second quarter worth approximately $29,000. Citigroup Inc. boosted its position in Oyster Point Pharma by 46.0% during the first quarter. Citigroup Inc. now owns 1,648 shares of the company’s stock worth $58,000 after purchasing an additional 519 shares during the period. First Mercantile Trust Co. bought a new stake in Oyster Point Pharma during the second quarter worth approximately $81,000. UBS Group AG boosted its position in Oyster Point Pharma by 19.3% during the second quarter. UBS Group AG now owns 3,907 shares of the company’s stock worth $113,000 after purchasing an additional 633 shares during the period. Finally, Bank of America Corp DE boosted its position in Oyster Point Pharma by 91.3% during the second quarter. Bank of America Corp DE now owns 3,993 shares of the company’s stock worth $115,000 after purchasing an additional 1,906 shares during the period. 72.82% of the stock is owned by hedge funds and other institutional investors.
Several research firms have recently weighed in on OYST. BidaskClub raised Oyster Point Pharma from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 8th. Zacks Investment Research raised Oyster Point Pharma from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Oyster Point Pharma presently has a consensus rating of “Buy” and an average target price of $42.80.
Oyster Point Pharma (NASDAQ:OYST) last issued its earnings results on Wednesday, August 5th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.15. Equities research analysts anticipate that Oyster Point Pharma will post -2.82 EPS for the current fiscal year.
Oyster Point Pharma Company Profile
Oyster Point Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. It is involved in developing OC-01, a nicotinic acetylcholine receptor agonist that is in Phase IIb clinical trial to treat the signs and symptoms of dry eye disease, as well as Phase III clinical trial for the neurotrophic keratitis.
See Also: Basic Economics
Want to see what other hedge funds are holding OYST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oyster Point Pharma (NASDAQ:OYST).
Receive News & Ratings for Oyster Point Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oyster Point Pharma and related companies with MarketBeat.com's FREE daily email newsletter.